Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $285.75 USD
Change Today -4.06 / -1.40%
Volume 1.9M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
Mexico
As of 8:04 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$290.45
Previous Close
$289.81
Day High
$290.99
Day Low
$285.00
52 Week High
03/20/15 - $317.72
52 Week Low
05/9/14 - $193.00
Market Cap
112.2B
Average Volume 10 Days
2.5M
EPS TTM
$2.46
Shares Outstanding
392.8M
EX-Date
--
P/E TM
116.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Details

Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

21,600 Employees
Last Reported Date: 02/18/15
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Executive Chairman
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $31.4K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $707.5K
President of Branded Pharma
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2014.

actavis plc (ACT) Key Developments

Actavis plc Announces Resignation of David Buchen as Executive Vice President, North American Generics and International

On May 1, 2015, David Buchen resigned as Executive Vice President, North American Generics and International of Actavis plc to pursue other interests. Following Mr. Buchen’s resignation, Mr. Buchen will provide certain transition consulting services to the company and its affiliates.

Actavis plc Announces Availability of AVYCAZ in US

Actavis plc has announced the availability of AVYCAZ, which is indicated for the treatment of bacterial infections, in the US. AVYCAZ is indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. As only limited clinical safety and efficacy data for AVYCAZ are currently available, AVYCAZ should be reserved for use in patients who have limited or no alternative treatment options. The addition of avibactam to ceftazidime protects ceftazidime from breakdown by Extended Spectrum Beta-Lactamases (ESBL), Klebsiella pneumoniae carbapenemase (KPC) and AmpC producing pathogens. AVYCAZ is part of Actavis' portfolio of infectious disease products that address some of the most dangerous pathogens. AVYCAZ received a priority review and FDA approval was supported in part by the FDA's previous findings of efficacy and safety of ceftazidime for the treatment of cIAI and cUTI. In addition, the contribution of avibactam to AVYCAZ was primarily established via in vitro data and animal models of infection. AVYCAZ was studied in two Phase II, randomized, blinded, active controlled, multicenter trials, one each in cIAI and cUTI, including pyelonephritis. These studies were not designed with any formal hypotheses for inferential testing against the active comparators. AVYCAZ for injection is supplied in single-use, clear glass vials for reconstitution. It is available to hospitals for purchase in cartons of ten (10) 2.5 g vials.

Actavis and Medicines360 Announce Publication of Results of ACCESS IUS Efficacy and Safety Study of LILETTA 52 Mg in Contraception

Actavis plc and Medicines360 announced that the initial results of ACCESS IUS (AComprehensive Contraceptive Efficacy and Safety Study of an IUS) were published online in the medical journal Contraception. The study found that LILETTA (levonorgestrel-releasing intrauterine system) 52 mg, is 99.45% effective for the prevention of pregnancy for up to three years of use in women aged 16-35 regardless of race, parity (previous births), or body mass index (BMI). The ACCESS IUS trial is still ongoing and will evaluate the efficacy and safety of LILETTA for up to seven years of use. The multicenter clinical trial was conducted by Medicines360 and is the first and only FDA-approval study for an IUD conducted exclusively in the U.S. ACCESS IUS was performed at 29 sites including public health clinics, private offices and University centers The study enrolled 1,751 women aged 16-45, including nearly 60% who had not previously given birth (nulliparous), the large group of such women ever included in an IUD approval study. Demographics mirrored the 2010 U.S. census; most women were Caucasian (78.4%) or Black/African American (13.3%), and 14.7% were of Hispanic ethnicity. The study had no upper BMI limit for enrollment and 25% of participants were obese. The primary study outcome was pregnancy rate in women aged 16-35 years. Pregnancies occurred in two nulliparous (never given birth) and four parous (previously given birth) participants. The pregnancy rate (measured as a Pearl Index) for LILETTA was 0.15 (95% CI 0.02, 0.55) per 100-women years during year one and 0.22 (95% CI 0.08, 0.49) per 100-women years through year three. The cumulative life-table pregnancy rate was 0.55 (95% CI 0.24, 1.23) through 3 years. The most common adverse events leading to discontinuation were expulsion (3.5%), bleeding complaints (1.5%), acne (1.3%) and mood swings (1.3%). Most expulsions occurred in the first year, consistent with expulsion timing seen with other IUDs. Of the 68 women followed for fertility after LILETTA discontinuation, 48 (70.6%) conceived spontaneously within six months and 59 (86.8%) within 12 months; the median time to conception was four months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $285.75 USD -4.06

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $65.03 USD -0.29
GlaxoSmithKline PLC 1,518 GBp +17.00
Medtronic PLC $74.91 USD -0.99
Novo Nordisk A/S kr369.60 DKK -1.00
Valeant Pharmaceuticals International Inc C$264.60 CAD -5.09
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 2.7x
Price/Cash Flow 117.7x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.ie. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.